# Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

> **NCT07552389** · PHASE3 · RECRUITING · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- Hypertension
- Diabete Type 2

## Interventions

- **DRUG:** Test group
- **DRUG:** Exploratory test group
- **DRUG:** Control group 1
- **DRUG:** Control group 2

## Key facts

- **NCT ID:** NCT07552389
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07552389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07552389, "Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07552389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*